Information Provided By: 
Fly News Breaks for January 4, 2018
ABT, DXCM
Jan 4, 2018 | 11:46 EDT
Cowen analyst Doug Schenkel believes shares of Dexcom (DXCM) are down too much after Abbott (ABT) announced Medicare reimbursement for Libre. Given Libre's dosing claim, this development was expected, though it came three months earlier than expected, Schenkel tells investors in a research note. He believes a 10% selloff "appears disproportionate" on a three month timing swing on an expected event. The analyst keeps an Outperform rating on Dexcom with a $70 price target. The stock in late morning trading is down 11% to $51.86.
News For DXCM;ABT From the Last 2 Days
DXCM
Apr 26, 2024 | 16:08 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
DXCM
Apr 26, 2024 | 12:03 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
DXCM
Apr 26, 2024 | 09:14 EDT
DXCM
Apr 26, 2024 | 07:45 EDT
Canaccord analyst William Plovanic raised the firm's price target on DexCom to $145 from $144 and keeps a Buy rating on the shares. The firm said they reported a slight;ly better than expected Q1 as the company raised the low-end and mid-point of its revenue guidance and reiterated its adjusted GM/OM/EBITDA margins for 2024.
DXCM
Apr 25, 2024 | 17:21 EDT
Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSSnap (SNAP) up... To see the rest of the story go to thefly.com. See Story Here
DXCM
Apr 25, 2024 | 16:05 EDT
DXCM
Apr 25, 2024 | 16:04 EDT
DXCM
Apr 25, 2024 | 15:11 EDT
Pre-earnings options volume in DexCom is 11.4x normal with calls leading puts 11:2. Implied volatility suggests the market is anticipating a move near 5.8%, or $8.05, after results are released. Median move over the past eight quarters is 5.4%.
DXCM
Apr 25, 2024 | 13:09 EDT
